Money

Found 79,340 articles

• AbCellera Reports Q1 2023 Business Results

  5/4/2023

  AbCellera announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

• Cerus Corporation Announces First Quarter 2023 Financial Results

  5/4/2023

  Cerus Corporation announced financial results for the first quarter ended March 31, 2023.

• Travere Therapeutics Reports First Quarter 2023 Financial Results

  5/4/2023

  Travere Therapeutics, Inc. reported its first quarter 2023 financial results and provided a corporate update.

• Helius Medical Technologies, Inc. to Release First Quarter 2023 Financial Results on May 11, 2023

  5/4/2023

  Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced that the Company will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes.

• Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration

  5/4/2023

  Vyant Bio, Inc. is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders.

• Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

  5/4/2023

  Cognition Therapeutics, Inc., a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, reported financial results for the first quarter ended March 31, 2023 and provided recent business updates.

• SenesTech to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

  5/4/2023

  SenesTech, Inc. will report financial results for its first quarter 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023.

• X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

  5/4/2023

  X4 Pharmaceuticals reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones.

• Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

  5/4/2023

  Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors reported financial results and business highlights for the first quarter ended March 31, 2023.

• NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

  5/4/2023

  NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, reported financial results for the quarterly period ended March 31, 2023 and provided business highlights.

• Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/4/2023

  Vir Biotechnology, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2023.

• Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results

  5/4/2023

  Protalix BioTherapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

• Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

  5/4/2023

  Cardiff Oncology, Inc. announced financial results for the first-quarter ended March 31, 2023, and provided a business update.

• Mettler-Toledo International Inc. Reports First Quarter 2023 Results

  5/4/2023

  Mettler-Toledo International Inc. announced first quarter results for 2023.

• Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)

  5/4/2023

  Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months ended March 31, 2023.

• Cytokinetics Reports First Quarter 2023 Financial Results

  5/4/2023

  Cytokinetics, Incorporated reported financial results for the first quarter of 2023. Net loss for the first quarter was $131.3 million, or $1.38 per share, compared to net loss for the first quarter of 2022 of $89.4 million, or $1.05 per share.

• OpGen Announces Closing of $3.5 Million Public Offering

  5/4/2023

  OpGen, Inc. announced the closing of its previously announced public offering of an aggregate of 4,495,825 shares of its common stock and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share and accompanying warrant.

• Reneo Announces Pricing of Public Offering of Common Stock - May 04, 2023

  5/4/2023

  Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 6,875,000 shares of its common stock at a public offering price of $8.00 per share for aggregate gross proceeds of approximately $55.0 million, before deducting underwriting discounts and commissions and offering expenses.

• Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

  5/4/2023

  Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, provided a business update and reported financial results for the quarter ended March 31, 2023.

•  Merrimack Reports First Quarter 2023 Financial Results

  5/4/2023

  Merrimack Pharmaceuticals, Inc. announced its first quarter 2023 financial results for the period ended March 31, 2023.